KLK3 and posterior cortical atrophy: Commercially developed PCa vaccines include CureVac’s CV9104, a self-adjuvanted full-length mRNA vaccine that targets the PCa antigens PSA, PSCA, PMSA, STEAP1, prostatic acid phosphatase (PAP), and mucin 1 [77].